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Abstract 
Background: The effects of streptozotocin (STZ)‑induced diabetes on heart metabolism and function after myocar‑
dial infarction (MI) remodelling were investigated in rats.
Methods: Fifteen days after STZ (50 mg/kg b.w. i.v.) injection, MI was induced by surgical occlusion of the left 
coronary artery. Two weeks after MI induction, contents of glycogen, ATP, free fatty acids and triacylglycerols (TG) and 
enzyme activities of glycolysis and Krebs cycle (hexokinase, glucose‑6‑phosphate dehydrogenase, phosphofructoki‑
nase, citrate synthase) and expression of carnitine palmitoyl‑CoA transferase I (a key enzyme of mitochondrial fatty 
acid oxidation) were measured in the left ventricle (LV). Plasma glucose, free fatty acids and triacylglycerol levels were 
determined. Ejection fraction (EF) and shortening fraction (SF) were also measured by echocardiography.
Results: Glycogen and TG contents were increased (p < 0.05) whereas ATP content was decreased in the LV of the 
non‑infarcted diabetic group when compared to the control group (p < 0.05). When compared to infarcted control 
rats (MI), the diabetic infarcted rats (DI) showed (p < 0.05): increased plasma glucose and TG levels, elevated free fatty 
acid levels and increased activity of, citrate synthase and decreased ATP levels in the LV. Infarct size was smaller in the 
DI group when compared to MI rats (p < 0.05), and this was associated with higher EF and SF (p < 0.05).
Conclusions: Systolic function was preserved or recovered more efficiently in the heart from diabetic rats two weeks 
after MI, possibly due to the high provision of glucose and free fatty acids from both plasma and heart glycogen and 
triacylglycerol stores.
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Background
Diabetic patients often present cardiomyopathy and 
increased risk of myocardial infarction, both of which 
are associated with a high rate of mortality [1]. How-
ever, experimental studies have demonstrated that the 
hyperglycemia in diabetic animals promote changes in 
the heart which reduce the intensity of the injury follow-
ing a permanent coronary artery ligation. Despite the 
relevance of these findings, this issue deserves further 
investigation. The response of uncontrolled hyperglyce-
mia on heart remodelling after ischemia is yet to be fully 
understood [2–8].
Most studies on heart infarction aimed to investigate 
the consequences of the diabetic condition in reperfu-
sion. Hearts from diabetic rats have been shown to be 
more sensitive to ischemia/reperfusion in some studies 
[9, 10] and to exhibit lower susceptibility in others. In 
these latter studies, decreased fatty acid (FFA) oxidation 
[11] and greater glycogenolysis during ischemia [12] are 
associated with reduced myocardial infarction area [13]. 
The effects of ischemia/reperfusion on cardioprotection 
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are dependent on shear stress, which induces endothelial 
dysfunction during myocardial reperfusion [14]. So, the 
consequences of reperfusion depend on duration of the 
preceding ischemia, the hyperglycemic state, and [15] on 
the rate of glucose and fatty acid oxidation [16, 17]. Stud-
ies involving permanent ischemia and hyperglycemia on 
cardioprotection have shown conflicting results.
Exposure to a high glucose medium or diabetes for 
short periods of time has been found to protect the heart 
against permanent ischemia. This may be due to the 
improved ventricular function, and reduced infarcted 
area and mortality reported for diabetic rats under 
ischemic heart injury [7, 8, 18]. Our group has previ-
ously demonstrated that hyperglycemia may promote 
the survival of heart cells by increasing angiogenesis [7] 
and/or by decreasing pro-oxidant damage. These find-
ings were associated to improvement in both redox bal-
ance and sympathetic control of the heart function [8]. 
Fifteen days after myocardial infarction, diabetic animals 
showed reduced infarct size and heart fibrosis area along 
with improved systolic function, increased expression of 
programmed cell survival genes, increased use of glu-
cose as fuel (as suggested by high GLUT-1 expression), 
and reduced intensity of inflammation [7]. However, the 
association between myocardial infarction and metabolic 
changes in the heart induced by diabetes needs to be fur-
ther investigated.
The main purpose of the present study was to examine 
the changes in glucose and fatty acid metabolism, and 
cardiac function in streptozotocin-induced diabetic rats 
during tissue remodeling after myocardial infarction. The 
following measurements were carried out in the blood: 
FFA, triacylglycerol (TG) and glucose levels. The follow-
ing metabolic parameters were measured in the heart: 
levels of FFA, TG, ATP, and glycogen and activities of 
enzymes of glycolysis and Krebs cycle (hexokinase, glu-
cose-6-phosphate dehydrogenase, phosphofructokinase, 
citrate synthase) and expression of carnitine palmitoyl-
CoA transferase I (a key enzyme of fatty acid oxida-
tion). The hypothesis of the present study was that the 
diabetic state provides a more favorable tissue remod-
eling condition and preserves heart function after a MI 
through changes in fatty acid and glucose metabolism in 
the heart. The protocol of ischemia induced by perma-
nent coronary ligation without reperfusion was chosen in 
order to: (1) exclude the jeopardizing effects of reperfu-
sion per se, such as shear stress and generation of reactive 
oxygen species (ROS), (2) avoid the combination of other 
complications of diabetes, such as the arteriosclero-
sis and reduced heart blood flow and (3) examine tissue 
remodeling after injury as an attempt to establish new 
therapeutic approaches in the management of patients 
who suffered an ischemic heart event.
Methods
Animals
Male Wistar rats (250–280  g) were obtained from the 
Animal Facility at the Medical School of the University of 
São Paulo, São Paulo, Brazil. The rats received standard 
laboratory chow and water ad  libitum and were housed 
in cages containing four to five animals at 22 °C in a 12-h 
dark-light cycle. All experimental procedures were con-
ducted according to the Guidelines for the Use and Care 
of Animals Research issued by the National Institute of 
Health, and complied with the ARRIVE guidelines for 
reporting animal research [19]. The protocol used was 
approved by the Ethics in Research Committee of the 
Medical School of the University of São Paulo. All experi-
mental procedures were conducted according to the 
National Institutes of Health Guidelines for the use and 
care of animals.
The rats were randomly assigned to four groups 
(n = 12 per group): normoglycemic control (C), diabetic 
(D), normoglycemic myocardial infarcted (MI), and dia-
betic myocardial infarcted (DI). The diabetic state (D and 
DI groups) was induced by a single i.v. injection of strep-
tozotocin (STZ, 50  mg/kg b.w; Sigma Chemical Co., St. 
Louis, MO, USA) dissolved in citrate buffer pH 4.5. This 
experimental protocol for induction of type I diabetes 
has been widely used [8, 20–23]. Body weight was weekly 
evaluated. Blood glucose concentration was measured to 
confirm diabetes-induced hyperglycemia at the begin-
ning of the 30-day experimental protocol, 24 h after STZ 
injection (Accu-Check Instant test, Boehringer Man-
nheim, Germany). The normoglycemic rats (the C and 
MI groups) received a single injection of citrate buffer. 
Myocardial infarction was induced in both DI and MI 
groups, according to the procedure described in the fol-
lowing section. All rats were monitored during 30 days. 
The schematic representation of the experimental proto-
col used is depicted in Fig. 1.
Fifteen days after STZ injection or administration of 
citrate buffer, MI and DI rats were anaesthetized (80 mg/
kg b.w. ketamine and 12  mg/kg b.w. xylazine, i.p.) and 
underwent myocardial infarction by surgical occlusion 
of the left coronary artery as previously described in sev-
eral studies [7, 8, 18, 22, 24]. C and D animals underwent 
sham surgery with no induction of myocardial infarction 
in order to determine the effects of the surgical proce-
dure itself.
Echocardiographic measurements in the heart
Echocardiography was performed at the end of the 
experimental protocol by an observer blinded to group 
allocation, according to the guidelines of the American 
Society of Echocardiography. Rats were anaesthetized 
as described above and images were obtained with a 
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10-14 mHz linear transducer in a SEQUOIA 512 (ACU-
SON Corporation, Mountain View, CA, USA) for meas-
urement of systolic function (ejection fraction-EF and 
fractional shortening-FS), as described in detail else-
where [23, 24].
MI size was estimated on the basis of akinesis or dys-
kinesis areas. Regions with systolic shortening were clas-
sified as normal, hypokinetic or absent (akinetic), and 
sections with paradoxical movement were considered 
dyskinetic. Myocardial infarction size was estimated as 
the ratio of the infarcted area to the total perimeter of 
the endocardial border of the LV (%) [25]. To confirm the 
echocardiographic measurements, MI size was also eval-
uated by dissecting the fibrous scar from the remaining 
LV muscle [7].
Experimental procedure
The animals were euthanized by decapitation after 
15  days of the myocardial infarction surgery or 30  days 
of induction of diabetes (Fig. 1). Plasma and left ventricle 
were removed and frozen at −70 °C.
Determination of free fatty acids and triacylglycerols
Plasma levels of FFA were evaluated using NEFA-HR kit 
(Wako Diagnostics, Richmond, VA, USA). Plasma sam-
ples (3  µL) were transferred to a 96-well plate and rea-
gents (200 µL) were added following the manufacturer’s 
instructions. Measurements of absorbance were carried 
out at 450  nm. Plasma TG concentrations were deter-
mined by enzymatic colorimetric assay following the 
manufacturer’s protocol (Bioclin®, Belo Horizonte, MG, 
Brazil).
For determination of TG and FFA levels in the LV, the 
heart tissue was homogenized in chloroform and metha-
nol solution (2:1). The lower phase was then transferred 
to a new tube and evaporated in a vacuum centrifuge. 
Lipid pellets were suspended in 100 µL absolute ethanol. 
The levels of FFA and TG were determined as described 
above.
Determination of glycogen content in the LV
Glycogen content of the LV was determined by using the 
assay described by Keppler and Decker [26]. This method 
is based on the conversion of glycogen into glucose by 
amyloglucosidase (Sigma,St. Louis. MO, USA). Glucose 
from glycogen was quantified using a glucose determina-
tion kit (Bioclin) and calculated as mg of glycosyl units/g 
wet weight of the LV.
Assays of the enzyme activities
LV protein extracts were sonicated for 30 s, at 4  °C, fol-
lowed by centrifugation at 1000g, at 4  °C, for 20  min. 
Total protein levels (Bradford method) [27] and maximal 
enzyme activity were measured in the supernatants.
Hexokinase (HK) activity was determined using the 
method described by Crabtree and Newsholme [28]. 
The extraction buffer contained Tris–HCl (50  mM) 
and EDTA (1  mM) at pH 7.4. The assay buffer con-
sisted of Tris–HCl (75  mM), MgCl2 (7.5  mM), EDTA 
(0.8  mM), KCl (1.5  mM), β-mercaptoethanol (4  mM), 
NADP+(0.4  mM), ATP (2.5  mM), glucose (1  mM), cre-
atine phosphate (10  mM), creatine kinase (1.8 U/mL), 
glucose-6-phosphate dehydrogenase (1.4 U per mL), and 
Triton X-100 (0.05 % v/v). The reaction was initiated by 
the addition of 50 μL glucose (1 mM final concentration) 
and absorbance measurement at 340 nm during 10 min.
To determine citrate synthase activity we used an 
extraction buffer containing 0.5 mM Tris–HCl and 1 mM 
EDTA, pH 7.4, and an assay buffer containing 100 mM), 
DTNB (0.2 mM), acetyl-CoA (0.1 mM), and Triton X-100 
(0.1  % v/v), pH 8.1. The reaction was initiated by the 
addition of 50 µL oxaloacetic acid (10 mM final concen-




§ STZ in the diabetic groups (D and
DI);




infarction in the groups:
MI and DI.
The rats of all groups (C, D,
MI and DI) were Killed.
Fig. 1 Experimental protocol used to study the effects of myocardial infarction and tissue remodelling on cardiac function and heart glucose and 
fatty acid metabolism in diabetic and control rats
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CPT1‑M (carnitine palmitoyltransferase I) expression
LV protein was extracted in a buffer containing Tris-
base (100 mM, pH 7.5); EDTA 10 mM; sodium fluoride 
100 mM; sodium pirophosphate 100 mM; sodium orto-
vanadate 10 mM; aprotinin 10 mg/mL, leupeptin 1 mg/
mL and PMSF 2  mM) and quantified by the Bradford 
method. Electrophoresis was performed in 7.5 % of slab 
gel in the presence of sodium dodecyl sulfate (SDS), 
according to the Laemmli method [30]. Electrotrans-
ference was performed for 42 min at a constant voltage 
(40  V) using a nitrocellulose membrane (Hybond ECL, 
GE Healthcare, Sweden). The membrane was incu-
bated in a 5 % non-fat dry milk blocking solution for 4 h 
before overnight incubation at room temperature with 
polyclonal antibodies at a dilution of 1:1000 (Santa Cruz 
Biotechnology, CA, USA). The subsequent steps were 
performed using the streptavidin/phosphatase alkaline 
system (GE Healthcare, Sweden), and the bands were 
revealed using NBT/BCIP substrates (Bio Rad Laborato-
ries, CA, USA) [31].
Determination of ATP level in the heart
LV was homogenized in perchloric acid (0.6 N) and the 
supernatant was neutralized using potassium bicarbo-
nate aqueous solution (1 M). A commercial kit from Inv-
itrogen (Eugene, Oregon, USA) was used to determine 
ATP concentration in the supernatant. The method is 
based on luciferase requirement for ATP in producing 
light (maximum emission at approximately 560  nm and 
pH 7.8). ATP levels were calculated as μM and expressed 
on the basis of wet tissue weight. A kit based on lucif-
erin/luciferase assay has also been recently used by other 
researchers for determination of ATP levels [32, 33].
Statistical analysis
Results are presented as mean ± SEM. One-way or two-
way ANOVA followed by the Student–Newman–Keuls 
post hoc test was used to compare the groups. Differ-
ences were considered significant at p  ≤  0.05 for all 
measurements.
Results
Indicators of the establishment of diabetic state
After 30  days of STZ injection, body weight was low-
ered in diabetic rats (D and DI groups) when compared 
to normoglycemic animals (C and MI groups) (Table 1). 
Plasma glucose levels were increased in STZ-induced 
diabetic rats. MI tissue remodelling did not markedly 
change blood glucose levels either in control or diabetic 
rats (Table 1). Plasma FFA and triacylglycerol levels were 
raised in non-infarcted diabetic rats (D group) when 
compared to the other groups (C, MI and DI). After MI 
tissue remodelling, plasma FA and triacylglycerol levels 
were decreased in diabetic rats (DI group) when com-
pared to non- infarcted diabetic rats (D group) (Table 1).
Myocardial infarct size
The myocardial infarction area of the heart was signifi-
cantly smaller (24 ± 3 % of the LV perimeter) in the dia-
betic group when compared to the MI group (39 ± 2 % of 
the LV perimeter) (Fig. 2a).
Systolic cardiac function
Systolic function, as indicated by FS (Fig.  2b) and EF 
(Fig. 2c), was impaired (FS: 25 ± 2 % and EF: 55 ± 3 %) 
in the MI group when compared to C (FS: 39 ± 1 % and 
EF: 71 ± 1 %) and D (FS: 39 ± 2 % and EF: 78 ± 2 %) rats. 
Systolic function was preserved after MI remodelling in 
diabetic rats (FS: 48 ± 2 % and EF: 82 ± 3 %).
Contents of free fatty acids and triacylglycerols in the left 
ventricle
The free fatty acid levels of the LV were increased in 
the DI group when compared to the remaining groups 
(Fig. 3a). Triacylglycerol levels in the LV were increased 
in the D group when compared to the other groups. After 
myocardial infarction, triacylglycerol levels of the LV 
were markedly decreased in diabetic rats (DI group) but 
remained unaltered in the control group (Fig. 3b).
Glycogen content in the left ventricle
Glycogen content of the LV was increased in the D group 
when compared to other rats (Fig.  3c). After MI tissue 
remodelling, glycogen content in the LV was decreased 
in diabetic animals but remained unaltered in the control 
group (Fig. 3c).
Enzyme activities of glycolysis and Krebs cycle in the heart
The maximum activity of G6PDH, phosphofruc-
tokinase, HK, and citrate synthase were meas-
ured. G6PDH and phosphofructokinase maximum 
Table 1 Measurements of  body weight, glucose, free 
fatty acids (FFA) and  triacylglycerol (TG) plasmatic levels 
after 15 days of myocardial infarction and 30 days of dia-
betes
Body weight, Glucose, FFA and TG levels in plasma (mg/dl) of control (C), 
diabetic (D), myocardial infarcted (MI) and diabetic myocardial infarcted (DI) rats. 
Data are reported as mean ± SEM
* p ≤ 0.05 compared with C; †  p ≤ 0.05 compared with MI; ‡ p ≤ 0.05 compared 
with D
Groups Body weight Glucose FFA TG
C 362 ± 16 87 ± 16 13 ± 1.4 82 ± 6
D 297 ± 16*† 433 ± 25*† 21 ± 3*† 252 ± 44*†
MI 378 ± 12 96 ± 3 15 ± 1.7 59 ± 6
DI 305 ± 19*† 411 ± 28*† 12 ± 0.9‡ 110 ± 19‡
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activity were not markedly changed. HK activity was 
decreased in the heart of diabetic animals; however, 
after infarction and tissue remodeling (DI group), the 
values reached those of control rats (C and MI groups) 
(Fig. 4a). Citrate synthase activity was not changed by 
diabetes. After MI tissue remodeling, citrate synthase 
activity was reduced in the heart of control rats (MI 
versus C) but it remained unchanged in the diabetic 
group (DI versus D). Citrate synthase activity, how-
ever, was lower in the heart of DI when compared to 
C rats (Fig. 4b).
CPT1‑M expression
The CPT1-M is an enzyme located in the inner mito-
chondrial membrane and plays a key role in the control 
of fatty oxidation. CPT1-M protein levels were decreased 
in the heart of D rats when compared to the remaining 
groups. Tissue remodeling abolished the decrease in 
CPT1-M expression observed in the heart of D rats (DI 
group), and values reached those of the C and MI groups 
(Fig. 5a).
ATP levels in the heart
ATP levels in the heart were decreased in the D, MI, and 
DI groups when compared to C rats. This reduction was 
more pronounced in DI rats (Fig. 5b).
Discussion
Remodeling plays a central role in cardiac tissue repair 
and has been associated to poor MI prognosis [17]. As 
previously reported by our group, diabetic rats show a 
smaller heart lesion area after 15  days of the MI when 
compared to normoglycemic animals. This reduction has 
been associated with decreased fibrosis and increased 
expression of cell survival markers, such as vascular 
endothelial growth factor [7], reduction in oxidative 
stress and attenuation of the sympathetic activity dys-
function [8]. The present study provides evidence that 
tissue remodeling after MI was able to preserve/recover 
more efficiently the systolic function in STZ-induced 
diabetic rats. In this sense, it should be emphasized that 
this experimental model of myocardial infarction allowed 
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Fig. 2 Echocardiographic parameters 15 days after myocardial infarction or after 30 days of diabetes. a Direct myocardial infarction area measure‑
ment in control myocardial infarcted (MI) and diabetic myocardial infarcted (DI) rats. b Fractional shortening and c Ejection fraction in normoglyce‑
mic control (C), diabetic (D), normoglycemic myocardial infarcted (MI) and diabetic myocardial infarcted (DI). Results are presented as mean ± SEM 
of 12 rats for each group. *p ≤ 0.05 compared with C; †p ≤ 0.05 compared with MI; ‡p ≤ 0.05 compared with D
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Fig. 3 a Free fatty acids; b triacylglycerols and c glycogen contents in the left ventricle of normoglycemic control (C), diabetic (D), normoglycemic 
myocardial infarcted (MI) and diabetic myocardial infarcted (DI) rats. Results are presented as mean ± SEM of 12 rats per group. *p ≤ 0.05 compared 



















































D IDC MI D IDC MI 
Fig. 4 Enzyme activity in the left ventricle of normoglycemic control (C), diabetic (D), normoglycemic myocardial infarcted (MI) and diabetic myo‑
cardial infarcted (DI) rats: a Hexokinase and b. Citrate synthase. Results are presented as mean ± SEM of 12 rats per group. *p ≤ 0.05 compared with 
C; ‡p ≤ 0.05 compared with D
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regardless of the chronic vascular complications usually 
associated with diabetic states. Also, the jeopardizing 
effects of reperfusion, such as shear stress and ROS pro-
duction, were prevented.
These results reported herein suggest that hyperglyce-
mia may trigger metabolic mechanisms that would ensure 
better remodeling after ischemic injury. High plasma glu-
cose levels are associated with increased expression of the 
hypoxia-inducible factor-1 alpha (HIF-1α). This transcrip-
tion factor responds to changes in oxygen supply and reg-
ulates blood flow and glucose uptake by increasing cardiac 
tissue vascularization prior to ischemia [7]. These changes 
seem to attenuate tissue injury under repeated ischemic 
insults, thus favoring the consequent remodeling pro-
cess. As a result, a new metabolic feature is established to 
ensure energy utilization efficiency and normal LV func-
tion, and an ischemic preconditioning-like state may be 
established in the heart from diabetic animals (Fig. 6).
Diabetic animals (D group) showed increased plasma 
levels of FFA and TG and raised LV levels of TG and gly-
cogen when compared to the control group before coro-
nary occlusion (Table  1; Fig.  3). This metabolic feature 
favored the remodeling of the ischemic cardiac tissue, 
thus preserving the systolic function. These findings sug-
gest that in diabetic condition the infarcted heart works 
well after remodeling under a lower ATP level state 
(Fig. 5b). The mechanisms involved in the heart metab-
olism and function interrelationship in diabetes need 
further investigation; however, we might hypothesize 
that this association serves to enhance ATP/ADP-AMP 
cycling and to promote changes in angiogenesis.
We contend that the changes in glucose and fatty acid 
metabolism in the heart induced by diabetes are largely 
responsible for the results of systolic function observed.
Tissue remodeling after MI in the heart of diabetic 
rats somehow benefited from the metabolic feature with 
hyperglycemia, increased plasma levels of FFA and TG, 
augmented heart glycogen and triacylglycerol contents, 
and reduced hexokinase activity, CPT1-M expression, 
and ATP levels/in the heart. The metabolic profile of the 
heart in diabetic state involves high uptake and oxida-
tion of fatty acids [34]. Randle et al. [35] have shown that 
increased plasma FFA concentrations reduce glucose uti-
lization and causes glycogen accumulation in the heart. 
As previously reported, [36] free fatty acids contribute to 
decrease glucose oxidation in the heart after 6 weeks of 
streptozotocin-induced diabetes. This effect of fatty acids 
is partially reversed by treatment with a CPT1 inhibitor.
Hirabara et  al. [37]. have shown that mitochondrial 
dysfunction in skeletal muscle cells treated with saturated 
fatty acids is associated with impaired glucose metabo-
lism and insulin resistance, increased phosphorylation 
of Akt and decreased phosphorylation of GSK-3, which 
phosphorylates and inhibits glycogen synthase activ-
ity [38]. Insulin treatment does not change either Akt or 
GSK- 3 phosphorylation but increases glycogen content 
in the heart [39]. The reduced glycogen and triacylglyc-
erol contents in the LV suggest that these metabolites are 
readily used when required by the heart. These findings 
may be associated with the changes in enzyme activi-
ties of glycolysis, increased FFA content, and decreased 
ATP levels and CPT1-M expression in the heart. The 
increased degradation of glycogen and TG might account 
for the smaller infarcted area and the preservation of 
the heart working capacity and systolic function found 
in the diabetic group. In fact, stored glycogen and TG 
are primary sources of energetic substrates to the heart, 













































Fig. 5 a CPT1‑M (carnitine palmitoyltransferase I) expression and b ATP contents in the left ventricle of normoglycemic control (C), diabetic (D), 
normoglycemic myocardial infarcted (MI) and diabetic myocardial infarcted (DI) rats. Results are presented as mean ± SEM of 8 rats per group. 
*p ≤ 0.05 compared with C; †p ≤ 0.05 compared with MI; #p ≤ 0.05 compared with DI; ‡p ≤ 0.05 compared with D
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injury and healing. Ranvigerova et  al. [12] have shown 
that after one-week streptozotocin-induced diabetes, 
rats have higher glycogen content in the left ventricle 
and increased glycogenolysis activity in the heart during 
ischemia. As a result, the heart becomes more resistant 
to ischemia-induced arrhythmias in diabetes when com-
pared to controls. Chu et  al. [13] have shown reduced 
infarcted area and higher glycogen content in the heart 
of diabetic pigs.
Malfitano et al. [40] and Egorova et al. [41] have found 
that the increase in glucose availability, the preferred 
energetic substrate for the heart in stress condition, is 
likely to play a key cardioprotective role under ischemia. 
Diabetes promotes a marked increase in plasma glucose 
and free fatty acid levels, thus increasing the availability 
of these metabolites to tissues and organs, including the 
heart. On the other hand, the intracellular provisions of 
glucose (from accumulated glycogen and plasma) and 
FFA (from stored triacylglycerols and plasma) in the 
heart from diabetic rats lead cardiomyocytes to gener-
ate oxaloacetate and acetyl-CoA in order to ensure the 
intense flux of metabolites through the Krebs cycle. 
In addition to the enhanced provision of glucose and 
free fatty acids from the plasma and inside the cells, 
increases in citrate synthase activity and in CPT1-M 
expression were also observed in the heart from dia-
betic rats.
These results suggest that the heart then adapts itself 
to work satisfactorily in a low ATP level condition in dia-
betic state. This mechanism does not work in a non-dia-
betic state. In fact, under this latter condition, myocardial 
infarction remodeling was associated with a slight reduc-
tion of ATP levels together with impaired heart function. 
Normoglycemic rats without increased levels of TG and 
FFA in plasma and LV do not develop the postulated 
ischemic preconditioning-like state and utilize energy 
ineffectively [42]. In the early stages, cardiac remod-
eling characterized by normal or slightly increased fatty 
acid (FA) oxidation plays a compensatory, cardioprotec-
tive role [43], so a new metabolic profile is established to 
ensure energy utilization efficiency and the preservation 
of LV function (Fig. 6). Peroxisome proliferator-activated 
receptor (PPAR)-alpha is downregulated in ischemic 
myocardium and has been found to play a role in the 
switch from fatty acid oxidation to glucose consumption 
[44].
In conclusion, the feature of heart glucose together with 
free fatty acid metabolism in diabetic animals before myo-
cardial infarction and remodeling ensure that the systolic 
function is preserved/recovered more efficiently when 
A new metabolic feature is established to 
ensure the energy utilization efficiency and 
preservation of the LV function.  
“Diabetes is an ischemic precondioning-like state”
Preference for the use of glucose 
associated to changes in oxygen supply 













Fig. 6 Diabetes is an ischemic preconditioning‑like state by increasing the HIF‑1α expression, leading to angiogenesis and modulating key meta‑
bolic pathways to optimize glucosea. After myocardial infarction, this heart is conditioned to increase the expression of glucose transporter 1 (Glut‑
1)a, activating glycolysis and FFA uptake (CPT1‑M)b. The O2 utilization in hypoxia to generate sufficient amounts of ATP without producing excessive 
amounts of ROSc, which would inhibit tricarboxylic acid cycle and mitochondrial respiration, promotes a positive remodeling, thus preserving the 
left ventricular function. a [7]; b present data; c [8]
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compared to normoglycemic infarcted animals. The dia-
betic animals presented reduced cardiac injury and a better 
systolic function performance associated with lower ATP 
levels in the left ventricle. We suggest that the diabetic state 
induces changes in cardiac metabolism which enhance the 
efficiency of tissue remodeling after ischemic injury.
Perspectives
Several therapeutic approaches involving metabolism 
have been suggested to mitigate the impairment of car-
diac function caused by myocardial infarction. For 
instance, Hughey et  al. [45] have examined the efficacy 
of mesenchymal stem cell transplantation to attenu-
ate the changes in cardiac function and intermediary 
metabolism found in myocardial infarction and insulin 
resistance. Evidence is presented herein that the diabetic 
state with hyperglycemia and increased levels of TG and 
FFA in plasma and heart protects may protect the heart 
against infarction. In fact, hypoglycemia onset as a con-
sequence of intensive control of blood glucose levels has 
been associated with increased cardiovascular mortal-
ity [46–49]. Liepinsh et  al. [50] have reported that the 
heart is better protected against myocardial infarction in 
the postprandial state due to high insulin-activated glu-
cose utilization. These observations led us to speculate 
that the induction of a diabetic- like metabolic condition 
may represent a potentially novel therapeutic approach 
to handle non diabetic patients undergoing an ischemic 
heart event.
Limitations of study
Further studies are needed to elucidate the mechanisms 
underlying the role played by the increased provision 
of glucose and free fatty acids on cardiac tissue remod-
eling after ischemia. One has to keep in mind that the 
improved cardiac function herein reported is probably 
transitory, lasting for a short period of time after MI. The 
occurrence of neuropathy and nephropathy in diabetic 
patients do impair cardiovascular function if hypergly-
cemia condition is maintained for a prolonged period of 
time.
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